Evidence verdict: The 2026 TranslAGE analysis is meaningful progress for trial design. Mortality- and pace-of-aging-oriented clocks were generally more responsive than first-generation chronological-age clocks, while pharmacological and lifestyle interventions showed stronger biomarker responses than several other categories. But responsiveness alone does not prove that changing a clock causes…
Evidence verdict: Human geroscience is testing mTOR inhibitors, metformin, senolytics, metabolic drugs, NAD-related strategies and biomarker-guided approaches. Most studies remain small, disease-specific, early phase or focused on surrogate measures. No completed trial has demonstrated that a drug extends human lifespan by targeting aging, so this tracker separates registered,…
Evidence verdict: The 2026 Nature Medicine review marks a shift from asking for one universal biological-age number toward mapping aging across organs, tissues and cell types. The field is becoming more predictive and clinically relevant, but aging clocks are still heterogeneous biomarkers rather than proven universal surrogate endpoints…
Evidence verdict: The influential 2023 Science paper suggested circulating taurine declines with age and could reflect an aging-related deficiency. More rigorous 2025 longitudinal and independent human data found the opposite pattern or no age association, making circulating taurine unsuitable as a universal aging biomarker. This does not, by…
2026 verdict: The 2025–2026 evidence strengthens the case that creatine can modestly augment lean mass and lower-body strength in older adults, especially alongside resistance training. New 2026 trials also report cognitive, inflammatory and metabolic signals, but many of those findings are exploratory and do not establish that creatine…
Evidence verdict: The 2026 systematic review supports biological activity from oral NMN and NR, but it does not establish that raising a blood or cellular NAD-related marker improves health, slows human aging or extends lifespan.
Bottom line: longevity science can increasingly measure biological aging and test interventions, but no single aging clock is a validated universal surrogate for healthspan or lifespan, and most proposed geroprotectors still lack definitive human outcome evidence.